Furthermore, whilst the study of pre-leukemic clones in AML is well advanced, this area is research is highly under-developed in CML, and warrants further attention, given that clinical grade compounds that target IDH1/2 (Popovici-Muller et al., 2018) are now available and have undergone clinical trials in AML. Here, IDH1 is linked to acute myeloid leukemia.